AveXis President Dave Lennon is standing behind the company’s high-cost, once-and-done SMA therapy, AVXS-101.
According to an Endpoint News report, Lennon said the treatment could be justifiably priced between $4 million and $5 million.
“Four million dollars is a significant amount of money, but we believe this is a cost-effective point,” Lennon told investors earlier this month. “We’ve shown through other studies we are cost effective in the range of $4 to $5 million. And ultimately, this is important context as we consider how we’re going to evaluate value for AVXS-101.”
Novartis, which owns AveXis, outlined their justification for the pricing, citing guidelines developed by the Institute for Clinical and Economic Review, per the report.